OBJECTIVE: We analyzed autoantibodies against tumor-associated antigens (TAAs) in the serum of patients with endometrioma and healthy controls to determine whether autoantibodies can be accurate biomarkers for the diagnosis of ovarian endometrioma. METHODS: Serum samples were obtained from 56 patients with endometriosis and 66 healthy women who served as normal controls. The titers of antibodies against a panel of eight TAAs were analyzed using enzyme-linked immunosorbent assay. RESULTS: We found that the serum IGFII mRNA-binding protein 1 (IMP1) autoantibody and cyclin B1 autoantibody could discriminate between healthy controls and endometriosis patients (AUC-ROC 0.777; 95% confidence interval [CI] 0.694-0.860, P<0.0005, and AUC-ROC 0.614; 95%confidence interval [CI] 0.513-0.714, P=0.031, respectively). Using 0.073 and 0.007 as the cutoff values for IMP1 and Cyclin B1 autoantibody, respectively, the sensitivity and specificity of IMP1 were 85.7 and 63.6%, respectively. When cylcin B1 was combined with IMP1, the specificity increased to 72.7% and the sensitivity slightly decreased to 83.9%. CONCLUSIONS: Our data suggest that IMP1 alone or combined with cyclin B1 seems to fulfill the requirements of sensitivity and specificity to become a useful clinical biomarker of endometrioma. However, further studies will be required to establish the predictive value and to support the clinical use of IMP1/cyclin B1 in the diagnosis and/or screening of endometriosis. J. Clin. Lab. Anal. 24:357-362, 2010.
OBJECTIVE: We analyzed autoantibodies against tumor-associated antigens (TAAs) in the serum of patients with endometrioma and healthy controls to determine whether autoantibodies can be accurate biomarkers for the diagnosis of ovarian endometrioma. METHODS: Serum samples were obtained from 56 patients with endometriosis and 66 healthy women who served as normal controls. The titers of antibodies against a panel of eight TAAs were analyzed using enzyme-linked immunosorbent assay. RESULTS: We found that the serum IGFII mRNA-binding protein 1 (IMP1) autoantibody and cyclin B1 autoantibody could discriminate between healthy controls and endometriosispatients (AUC-ROC 0.777; 95% confidence interval [CI] 0.694-0.860, P<0.0005, and AUC-ROC 0.614; 95%confidence interval [CI] 0.513-0.714, P=0.031, respectively). Using 0.073 and 0.007 as the cutoff values for IMP1 and Cyclin B1 autoantibody, respectively, the sensitivity and specificity of IMP1 were 85.7 and 63.6%, respectively. When cylcin B1 was combined with IMP1, the specificity increased to 72.7% and the sensitivity slightly decreased to 83.9%. CONCLUSIONS: Our data suggest that IMP1 alone or combined with cyclin B1 seems to fulfill the requirements of sensitivity and specificity to become a useful clinical biomarker of endometrioma. However, further studies will be required to establish the predictive value and to support the clinical use of IMP1/cyclin B1 in the diagnosis and/or screening of endometriosis. J. Clin. Lab. Anal. 24:357-362, 2010.
Authors: Jian-Ying Zhang; Roxanne Megliorino; Xuan-Xian Peng; Eng M Tan; Yao Chen; Edward K L Chan Journal: J Hepatol Date: 2006-09-25 Impact factor: 25.083
Authors: P Ioannidis; T Trangas; E Dimitriadis; M Samiotaki; I Kyriazoglou; C M Tsiapalis; C Kittas; N Agnantis; F C Nielsen; J Nielsen; J Christiansen; N Pandis Journal: Int J Cancer Date: 2001-11 Impact factor: 7.396
Authors: Panayotis Ioannidis; Louisa G Mahaira; Sonia A Perez; Angelos D Gritzapis; Panagiota A Sotiropoulou; Giannis J Kavalakis; Aris I Antsaklis; Constantin N Baxevanis; Michael Papamichail Journal: J Biol Chem Date: 2005-03-14 Impact factor: 5.157
Authors: Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull Journal: Cochrane Database Syst Rev Date: 2016-05-01
Authors: Costin Vlad Anastasiu; Marius Alexandru Moga; Andrea Elena Neculau; Andreea Bălan; Ioan Scârneciu; Roxana Maria Dragomir; Ana-Maria Dull; Liana-Maria Chicea Journal: Int J Mol Sci Date: 2020-03-04 Impact factor: 5.923